Home › Funds › Spruce Street Capital LP › ERAS
Spruce Street Capital LP position in ERAS
ERASCA INC · Health Care
Spruce Street Capital LP reported holding 422,543 shares of ERAS (ERASCA INC) in its Q3 2026 13F filing — a position valued at US$6.2M, representing 0.98% of its reported portfolio and ranking #25 among its reported holdings. Spruce Street Capital LP has disclosed ERAS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Spruce Street Capital LP's ERAS position evolved
Spruce Street Capital LP first disclosed a stake in ERAS in Q4 2025 at 3,889,632 shares (US$14.5M). Across 4 filings, Spruce Street Capital LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 422,543 shares valued at US$6.2M. Notable position changes include a 89% trim in Q1 2026 (shares rose 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 3.89M | $14.47M | New |
| Q1 2026 | 422.54K | $6.84M | Reduce |
| Q2 2026 | 422.54K | $7.74M | Hold |
| Q3 2026 | 422.54K | $6.19M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ERAS and 13F data
ERAS (ERASCA INC) is a Health Care company. 74 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$457.5M), RTW INVESTMENTS, LP (US$328.8M), Venrock Adviser, LLC (US$327.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ERAS
- Frazier Life Sciences Management, L.P. 24.98M sh · $457.55M · Q2 2026
- RTW INVESTMENTS, LP 17.95M sh · $328.78M · Q2 2026
- Venrock Adviser, LLC 17.89M sh · $327.78M · Q2 2026
- Logos Global Management LP 12.15M sh · $222.59M · Q2 2026
- Siren, L.L.C. 13.20M sh · $193.48M · Q3 2026
- Paradigm Biocapital Advisors LP 9.55M sh · $174.96M · Q2 2026
- ARCH Venture Management, LLC 7.09M sh · $129.92M · Q2 2026
- Cormorant Asset Management, LP 6.00M sh · $109.92M · Q2 2026
- Affinity Asset Advisors, LLC 5.59M sh · $81.96M · Q3 2026
- Vivo Capital, LLC 4.02M sh · $58.94M · Q3 2026
- a16z Capital Management, L.L.C. 2.86M sh · $52.44M · Q2 2026
- Soleus Capital Management, L.P. 2.70M sh · $49.46M · Q2 2026
More on Spruce Street Capital LP
FAQ
How long has Spruce Street Capital LP held ERAS?
Spruce Street Capital LP has disclosed ERAS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Spruce Street Capital LP's current position in ERAS?
As of Q3 2026, Spruce Street Capital LP holds 422.54K shares of ERAS (ERASCA INC), valued at $6.19M, representing 0.98% of its reported portfolio and ranking #25.
Has Spruce Street Capital LP been buying or selling ERAS?
In the latest 13F filing (Q3 2026), Spruce Street Capital LP held unchanged its position in ERAS.
Which other funds hold ERAS?
Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.